Opexa Therapeutics: Corporate Presentation (Opexa Therapeutics) - Jul 9, 2014 - "TERMS Study"; "A Completed Phase IIb Clinical Trial in RRMS"; "mITT population (n=142): 37% reduction in ARR vs. placebo; ARR 0.214 vs. 0.339"; "Superior safety and promising efficacy trend demonstrated"
P2b data • Multiple Sclerosis
|